Enzalutamide (MDV3100) CAS No.:915087-33-1

Enzalutamide (MDV3100) is a revolutionary and innovative cancer drug that has shown impressive results in treating prostate cancer. This drug is a potent androgen receptor inhibitor that works by blocking the activity of androgens, which promote the growth of cancer cells in the prostate gland.

Enzalutamide (MDV3100) is a small molecule that blocks the androgen receptor from binding to testosterone, which is a key hormone that fuels the growth of prostate cancer. By blocking this pathway, Enzalutamide (MDV3100) can slow down the growth of cancer cells in the prostate gland, shrink the size of the tumor, and reduce the risk of cancer progression.

Prostate cancer is the second leading cause of cancer deaths in men in the United States, and it is estimated that one in nine men will be diagnosed with prostate cancer during their lifetime. Enzalutamide (MDV3100) has shown impressive results in improving overall survival and delaying disease progression in patients with castration-resistant prostate cancer.

Enzalutamide (MDV3100) has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is also being investigated for the treatment of other types of cancer, such as breast cancer and non-small cell lung cancer.

Enzalutamide (MDV3100) is taken orally, and it is generally well-tolerated. The most common side effects associated with Enzalutamide (MDV3100) are fatigue, constipation, hot flashes, and nausea. However, these side effects are usually mild and can be managed with supportive care.

Enzalutamide (MDV3100) is a game-changer in the field of cancer therapy, and it has the potential to revolutionize the way we treat prostate cancer. Its impressive results in clinical trials have made it a promising option for patients with mCRPC who have failed other treatment options.

As a manufacturer of Enzalutamide (MDV3100), we take pride in producing high-quality products that meet the rigorous standards of the pharmaceutical industry. Our Enzalutamide (MDV3100) is manufactured in state-of-the-art facilities and undergoes rigorous quality control procedures to ensure that it meets the highest standards of purity, potency, and safety.

We are committed to providing our customers with the best possible service and support. Our knowledgeable and experienced team of professionals is dedicated to helping our customers succeed in their business ventures. We offer competitive pricing, efficient delivery times, and unparalleled customer service to ensure that our customers are completely satisfied with our products and services.

In conclusion, Enzalutamide (MDV3100) is a groundbreaking cancer drug that has the potential to revolutionize the way we treat prostate cancer. Its impressive results in clinical trials have made it a promising option for patients with mCRPC who have failed other treatment options. As a manufacturer of Enzalutamide (MDV3100), we are committed to providing our customers with the highest quality products and services to ensure their success. Contact us today to learn more about our Enzalutamide (MDV3100) and how it can benefit your business.

Chemical Structure : Enzalutamide

CAS No.: 915087-33-1

 

Enzalutamide(MDV3100;MDV-3100;MDV 3100)

Catalog No.: URK-V625 Only Used For Lab.

An androgen-receptor (AR) antagonist with IC50 of 36 nM.

Biological Activity

An androgen-receptor (AR) antagonist with IC50 of 36 nM; reduces the efficiency of AR nuclear translocation, and impairs both DNA binding to androgen response elements and recruitment of coactivators; induces tumor regression in mouse models of castration-resistant human prostate cancer; orally available.
Prostate cancer
Approved

Physicochemical Properties

References

1. Tran C, et al. Science. 2009 May 8;324(5928):787-90.

2. Richards J, et al. Cancer Res. 2012 May 1;72(9):2176-82.

3. Scher HI, et al. N Engl J Med. 2012 Sep 27;367(13):1187-97.

URK-V625_COA

URK-V625_SDS

URK-V625_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• Our experienced team is committed to providing our customers with the support they need to be successful in their research.
• With its high-quality products, advanced production technology and brand-new management concept, our products have sold well in China and many countries in the world.
• We take pride in knowing that our products are making a difference in the world of scientific research.
• We have established an energetic market service system and a quick response technical support system.
• Our Nuclear Receptor/Transcription Factor Library products are used by leading researchers and scientists around the world.
• We win many reliable customers by rich experience, advanced equipments, skilled teams, strict quality control and best service.
• You can trust us to provide you with the highest quality Nuclear Receptor/Transcription Factor Library products on the market.
• In the spirit of 'your needs, our innovation,' we focus on developing Enzalutamide (MDV3100) CAS No.:915087-33-1. We are proud of quality products that meet customer needs. We embrace various businesses with people worldwide.
• We take great care in ensuring that our products meet the highest standards.
• To become the stage of realizing dreams of our employees!

Hot Tags: enzalutamide (mdv3100) cas no.:915087-33-1, China enzalutamide (mdv3100) cas no.:915087-33-1, agonists for immune system modulation, epigenetic library for epigenetic analysis of epigenetic evolution, agonists for antibody therapy, epigenetic library for epigenetic analysis of epigenetic phenotype, inhibitors for peptide activity, epigenetic library for epigenetic regulation of cell senescence